Dr. Lewis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3401 Enterprise Pkwy
Ste 300
Beachwood, OH 44122Phone+1 216-831-5700Fax+1 216-831-1959- Is this information wrong?
Summary
- Dr. Lewis received his BS degree magna cum laude from Xavier University and his MD degree from the University of Cincinnati College of Medicine. His ophthalmology residency was at the University of Cincinnati Medical Center and his vitreoretinal surgery fellowship was at the University of Chicago.
Dr. Lewis's principal areas of interest are macular surgery, retinal detachment surgery, age-related macular degeneration, diabetic retinopathy, and retinal lasers.
Education & Training
University of ChicagoFellowship, Surgical Retina and Vitreous, 2013 - 2015
University of Cincinnati Medical Center/College of MedicineResidency, Ophthalmology, 2010 - 2013
TriHealth (Good Samaritan Hospital)Internship, Internal Medicine, 2009 - 2010
University of Cincinnati College of MedicineClass of 2009
Xavier UniversityB.S., Biology, Magna Cum Laude, 2001 - 2005
Certifications & Licensure
OH State Medical License 2015 - 2026
PA State Medical License 2019 - 2024
IL State Medical License 2013 - 2017- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Joseph Peters Scholarship Award 2003
- Schawe Scholarship 2001
Publications & Presentations
PubMed
- Early surgical displacement of submacular hemorrhage without tissue plasminogen activator use: one-year outcomes.Marwan Abdulaal, Richard Donkor, Jacobi Robertson, Shawn Lewis, David G Miller, Jerome Schartman, Sean Platt, Joseph M Coney> ;Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie. 2023 Nov 1
- 7 citationsSwitching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular d...Joseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Thomas P Hull, Shawn A Lewis, David G Miller, Michael A Novak, Scott D Pendergast, Han...> ;International Journal of Retina and Vitreous. 2023 Feb 1
- One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.Coney, J., McCoy, J., Buxy Sinha, S., Sonbolian, N., Zhou, L., Hull, T., Lewis, S., Miller, D., Novak, M., Pendergast, S., Pham, H., Platt, S., Rao, L., Schartman, J.,...> ;Clinical Ophthalmology. 2023 Jan 1
- Join now to see all
Journal Articles
- Acute exudative polymorphous paraneoplastic vitelliform maculopathy in a patient with carcinoma, not melanomaGrunwald L, Kligman B, Shields C, Arch Ophthalmol, 1/1/2011
- Chemical modulation of the chaperone function of human 5-A-crystallinBiswas A, Lewis S, Wang B, Miyagi M. Santoshkumar P, Gangadhariah MH, Nagaraj RH, J Biochem, 1/1/2008
- Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injuryGopez J, Yue H, Vasudevan R, Malik A. Fogelsanger L, Lewis S, Panikashvili D, Shohami E, Jansen S, Narayan R, Strauss K, Neurosurgery, 1/1/2005
Press Mentions
Coronavirus: London, Ont., Councillors Call for Discussion on Mandatory Masks PolicyJuly 14th, 2020- Retinal Toxicity Associated with MEK Inhibitor Use for Metastatic Cancer: A Rising Trend in OphthalmologyMay 18th, 2016
Hospital Affiliations
Mercy Health - St. Elizabeth Youngstown HospitalYoungstown, Ohio
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
